NewAmsterdam Pharma Files 8-K
Ticker: NAMSW · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1936258
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
NAP filed an 8-K on 12/10/24 for Reg FD and financials.
AI Summary
NewAmsterdam Pharma Company N.V. filed an 8-K on December 10, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in The Netherlands, has its principal executive offices in Naarden.
Why It Matters
This filing indicates routine corporate reporting, providing updates on financial statements and regulatory disclosures for NewAmsterdam Pharma Company N.V.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for corporate disclosures and does not appear to contain significant new risks.
Key Players & Entities
- NewAmsterdam Pharma Company N.V. (company) — Registrant
- December 10, 2024 (date) — Date of earliest event reported
- The Netherlands (location) — State or other jurisdiction of incorporation
- Naarden (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, covering Regulation FD Disclosure and Financial Statements and Exhibits.
When was this report filed?
The report was filed as of December 10, 2024.
Where is NewAmsterdam Pharma Company N.V. incorporated?
The company is incorporated in The Netherlands.
What is the company's principal executive office address?
The principal executive offices are located at Gooimeer 2-35, Naarden, The Netherlands, 1411 DC.
What is the registrant's telephone number?
The registrant's telephone number is +31 (0) 35 206 2971.
Filing Stats: 672 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-12-10 07:24:10
Filing Documents
- d910195d8k.htm (8-K) — 30KB
- d910195dex991.htm (EX-99.1) — 41KB
- d910195dex992.htm (EX-99.2) — 27KB
- g910195ex99_2p10g1.jpg (GRAPHIC) — 163KB
- g910195ex99_2p11g1.jpg (GRAPHIC) — 171KB
- g910195ex99_2p12g1.jpg (GRAPHIC) — 175KB
- g910195ex99_2p13g1.jpg (GRAPHIC) — 274KB
- g910195ex99_2p14g1.jpg (GRAPHIC) — 304KB
- g910195ex99_2p15g1.jpg (GRAPHIC) — 162KB
- g910195ex99_2p16g1.jpg (GRAPHIC) — 279KB
- g910195ex99_2p17g1.jpg (GRAPHIC) — 191KB
- g910195ex99_2p18g1.jpg (GRAPHIC) — 335KB
- g910195ex99_2p19g1.jpg (GRAPHIC) — 344KB
- g910195ex99_2p1g1.jpg (GRAPHIC) — 453KB
- g910195ex99_2p20g1.jpg (GRAPHIC) — 248KB
- g910195ex99_2p2g1.jpg (GRAPHIC) — 719KB
- g910195ex99_2p3g1.jpg (GRAPHIC) — 252KB
- g910195ex99_2p4g1.jpg (GRAPHIC) — 221KB
- g910195ex99_2p5g1.jpg (GRAPHIC) — 277KB
- g910195ex99_2p6g1.jpg (GRAPHIC) — 252KB
- g910195ex99_2p7g1.jpg (GRAPHIC) — 235KB
- g910195ex99_2p8g1.jpg (GRAPHIC) — 274KB
- g910195ex99_2p9g1.jpg (GRAPHIC) — 209KB
- 0001193125-24-273959.txt ( ) — 7910KB
- nams-20241210.xsd (EX-101.SCH) — 3KB
- nams-20241210_def.xml (EX-101.DEF) — 14KB
- nams-20241210_lab.xml (EX-101.LAB) — 23KB
- nams-20241210_pre.xml (EX-101.PRE) — 15KB
- d910195d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 Press Release, dated December 10, 2024. 99.2 NewAmsterdam Pharma Company N.V., December 10, 2024 BROADWAY Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: December 10, 2024